KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer

Yanhong Deng(Sun Yat-sen University), Jianping Wang(Sun Yat-sen University), Dianke Chen(Sun Yat-sen University), Jun Zhu(China National Nuclear Corporation), Yue Cai(Sun Yat-sen University), Shuyun Tan(Sun Yat-sen University), George P. Kim(Mayo Clinic in Arizona), Lei Wang(Sun Yat-sen University), Xinhui Fu(Sun Yat-sen University), Li Wang(China Three Gorges University), Ruoxu Dou(General Hospital of Guangzhou Military Command)
Molecular Oncology
March 27, 2015
10.1016/j.molonc.2015.03.006
Cited by 60

Related Papers

Gene expression elucidates functional impact of polygenic risk for schizophrenia
|Nature Neuroscience|2016|1.2k
<i>Fusobacterium nucleatum</i>in colorectal carcinoma tissue and patient prognosis
|Gut|2015|1.1k
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410